Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Apatinib in Combination With Ifosfamide and Etoposide (IE) for Relapsed or Refractory Osteosarcoma Progressed Upon First-line Chemotherapy (AIEO): a Prospective, Multiple-centre, Single-arm, Phase 2 Trial

NCT04824352 is registered in ClinicalTrials.gov with Peking University People's Hospital as lead sponsor.

NCT NCT04824352
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04824352 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Apatinib in Combination With Ifosfamide and Etoposide (IE) for Relapsed or Refractory Osteosarcoma Progressed Upon First-line Chemotherapy (AIEO): a Prospective, Multiple-centre, Single-arm, Phase 2 Trial
Lead sponsor
Peking University People's Hospital
Phase
Phase 2
Overall status
Suspended
Start date
April 1, 2021
Completion date
April 1, 2026
Enrollment
44 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

effect of drug, toxicity, drug